Tenaya Therapeutics to Participate in Upcoming Investor and Industry Conferences
Tenaya Therapeutics, Inc. (
NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today that Faraz Ali, Chief Executive Officer, is scheduled to participate in the Chardan 5th Annual Genetic Medicines Conference, the Alliance for Regenerative Medicine’s Cell and Gene Meeting on the Mesa and the Jefferies Gene Therapy/Editing Summit in October. Details of the presentations are as follows:
Tenaya Therapeutics Unveils Preclinical Research Supporting Product Candidate for Rare and Prevalent Heart Disease Indications at ESC Heart Failure 2021
Tenaya Therapeutics, a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, has unveiled preclinical data supporting drug discovery efforts involving its Precision Medicine Platform at the European Society of Cardiology Heart Failure 2021 (ESC-HF) meeting. The company shared data illustrating the use of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) to identify cardioprotective agents, as well as data supporting the beneficial effect of its proprietary and highly specific histone deacetylase 6 inhibitors (HDAC6i) – including TYA-11631 and TYA-11018 – in models of heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM).
Tenaya Therapeutics Announces New Appointments to Leadership Team
Tenaya Therapeutics, a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced the hires of Leone Patterson, MBA, as Chief Financial and Business Officer and Matthew Pollman, MD, MS, as Senior Vice President, Clinical Development. Ms. Patterson will lead corporate finance, investor relations, business development and corporate communications, as well as various operational functions, while Dr. Pollman will lead clinical development as well as efforts to develop novel delivery methods for cardiac gene therapy.
Tenaya Therapeutics Receives Orphan Drug Designation and Presents Pre-Clinical Data for its Most Advanced Gene Therapy Product Candidate for Genetic Hypertrophic Cardiomyopathy
Tenaya Therapeutics, a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for TN-201, its most advanced product candidate from its proprietary Gene Therapy Platform.
